Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2018
At a glance
- Drugs Bumetanide (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- 23 Mar 2017 New trial record